Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
BMJ Open. 2023 Apr 21;13(4):e070003. doi: 10.1136/bmjopen-2022-070003.
This study aimed to determine the oral carriage prevalence of species and identify factors associated with the carriage of species among patients with cancer on treatment.
A hospital-based cross-sectional study.
The study was conducted at a tertiary-level cancer hospital Ocean Road Cancer Institute (ORCI), Dar es Salaam, Tanzania.
We enrolled 196 participants who consented to join the study. Oral swabs were collected from all participants and inoculated onto Sabouraud dextrose agar supplemented with 50 mg/mL gentamicin and 50 mg/mL chloramphenicol, and chromogenic agar for phenotypic identification of species.
The study reported the high prevalence of oral carriage of species among patients with cancer on treatment at the tertiary-level cancer hospital in Dar es Salaam, Tanzania.
A total of 196 participants were enrolled in the study. The overall oral carriage of species was 37.8% (74/196). The prevalence was higher among patients undergoing chemotherapy and radiotherapy (44.4%) than those in monotherapy (13.3% chemotherapy, 20% radiotherapy). was the most common isolated species, 48.6% (36/74). Head and neck (adjusted OR (aOR) 15.09, 95% CI 3.05 to 74.59, p=0.00), gastrointestinal (aOR 14.14, 95% CI 2.25 to 88.63, p=0.00) malignancies and diabetes (aOR 3.18, 95% CI 1.03 to 9.77, p=0.04) were factors independently associated with oral carriage of species.
The oral carriage of species among patients with cancer receiving treatment at ORCI is high, mainly due to species. This is alarming since has intrinsic resistance to fluconazole, a common antifungal agent used to manage adult fungal infections. Therefore, efforts should be put into conducting regular check-ups for such opportunistic pathogens as they can lead to subsequent infections. Furthermore, studies conducted to determine the antifungal profile of the causative agents are warranted since different causative agents might have different profiles.
本研究旨在确定治疗中癌症患者携带 种的口腔携带率，并确定与 种携带相关的因素。
一项基于医院的横断面研究。
坦桑尼亚达累斯萨拉姆的三级癌症医院海洋路癌症研究所（ORCI）。
我们招募了 196 名同意参加研究的参与者。从所有参与者中采集口腔拭子，并接种到含有 50mg/ml 庆大霉素和 50mg/ml 氯霉素的萨布罗葡萄糖琼脂和显色琼脂上，以表型鉴定 种。
本研究报告了坦桑尼亚达累斯萨拉姆三级癌症医院治疗中的癌症患者口腔携带 种的高流行率。
共有 196 名参与者入组本研究。 种的总口腔携带率为 37.8%（74/196）。接受化疗和放疗的患者（44.4%）比接受单一治疗的患者（化疗 13.3%，放疗 20%）携带率更高。 是最常见的分离种，占 48.6%（36/74）。头颈部（调整后的 OR（aOR）15.09，95%CI 3.05 至 74.59，p=0.00）、胃肠道（aOR 14.14，95%CI 2.25 至 88.63，p=0.00）恶性肿瘤和糖尿病（aOR 3.18，95%CI 1.03 至 9.77，p=0.04）是与 种口腔携带相关的独立因素。
ORCI 接受治疗的癌症患者中 种的口腔携带率较高，主要是由于 种。这令人警惕，因为 对氟康唑具有固有耐药性，氟康唑是一种常用的抗真菌药物，用于治疗成人真菌感染。因此，应努力定期检查这些机会性病原体，因为它们可能导致随后的感染。此外，由于不同的病原体可能具有不同的特征，因此进行确定病原体抗真菌谱的研究是有必要的。
